217 related articles for article (PubMed ID: 27259012)
1. Pure Apocrine Carcinomas Represent a Clinicopathologically Distinct Androgen Receptor-Positive Subset of Triple-Negative Breast Cancers.
Mills AM; E Gottlieb C; M Wendroth S; M Brenin C; Atkins KA
Am J Surg Pathol; 2016 Aug; 40(8):1109-16. PubMed ID: 27259012
[TBL] [Abstract][Full Text] [Related]
2. Apocrine carcinoma as triple-negative breast cancer: novel definition of apocrine-type carcinoma as estrogen/progesterone receptor-negative and androgen receptor-positive invasive ductal carcinoma.
Tsutsumi Y
Jpn J Clin Oncol; 2012 May; 42(5):375-86. PubMed ID: 22450930
[TBL] [Abstract][Full Text] [Related]
3. Expression of apocrine differentiation markers in neuroendocrine breast carcinomas of aged women.
Sapino A; Righi L; Cassoni P; Papotti M; Gugliotta P; Bussolati G
Mod Pathol; 2001 Aug; 14(8):768-76. PubMed ID: 11504836
[TBL] [Abstract][Full Text] [Related]
4. Expression of GCDFP-15 and AR decreases in larger or node-positive apocrine carcinomas of the breast.
Honma N; Takubo K; Akiyama F; Sawabe M; Arai T; Younes M; Kasumi F; Sakamoto G
Histopathology; 2005 Aug; 47(2):195-201. PubMed ID: 16045781
[TBL] [Abstract][Full Text] [Related]
5. Androgen receptor in breast cancer: expression in estrogen receptor-positive tumors and in estrogen receptor-negative tumors with apocrine differentiation.
Niemeier LA; Dabbs DJ; Beriwal S; Striebel JM; Bhargava R
Mod Pathol; 2010 Feb; 23(2):205-12. PubMed ID: 19898421
[TBL] [Abstract][Full Text] [Related]
6. Expression patterns of GATA3 and the androgen receptor are strongly correlated in patients with triple-negative breast cancer.
Kim S; Moon BI; Lim W; Park S; Cho MS; Sung SH
Hum Pathol; 2016 Sep; 55():190-5. PubMed ID: 27184484
[TBL] [Abstract][Full Text] [Related]
7. The expression of GHRH and its receptors in breast carcinomas with apocrine differentiation-further evidence of the presence of a GHRH pathway in these tumors.
Kővári B; Vranic S; Marchio C; Sapino A; Cserni G
Hum Pathol; 2017 Jun; 64():164-170. PubMed ID: 28438614
[TBL] [Abstract][Full Text] [Related]
8. Triple Negative Apocrine Carcinomas as a Distinct Subtype of Triple Negative Breast Cancer: A Case-control Study.
Meattini I; Pezzulla D; Saieva C; Bernini M; Orzalesi L; Sanchez LJ; Desideri I; Francolini G; Bonomo P; Greto D; Loi M; Mangoni M; Bruni A; Nori J; Vezzosi V; Bianchi S; Livi L
Clin Breast Cancer; 2018 Oct; 18(5):e773-e780. PubMed ID: 29573977
[TBL] [Abstract][Full Text] [Related]
9. Apocrine lesions of the breast: part 2 of a two-part review. Invasive apocrine carcinoma, the molecular apocrine signature and utility of immunohistochemistry in the diagnosis of apocrine lesions of the breast.
D'Arcy C; Quinn CM
J Clin Pathol; 2019 Jan; 72(1):7-11. PubMed ID: 30425121
[TBL] [Abstract][Full Text] [Related]
10. An Update on the Molecular and Clinical Characteristics of Apocrine Carcinoma of the Breast.
Vranic S; Gatalica Z
Clin Breast Cancer; 2022 Jun; 22(4):e576-e585. PubMed ID: 35027319
[TBL] [Abstract][Full Text] [Related]
11. Immunohistochemical analysis of apocrine breast lesions. Consistent over-expression of androgen receptor accompanied by the loss of estrogen and progesterone receptors in apocrine metaplasia and apocrine carcinoma in situ.
Gatalica Z
Pathol Res Pract; 1997; 193(11-12):753-8. PubMed ID: 9521507
[TBL] [Abstract][Full Text] [Related]
12. α-Methylacyl-CoA racemase: a useful immunohistochemical marker of breast carcinoma with apocrine differentiation.
Nakamura H; Kukita Y; Kunimasa K; Kittaka N; Kusama H; Nakayama T; Tamaki Y; Sugiura R; Yasuda H; Hashimoto M; Yamamoto T; Imamura F; Nakatsuka SI
Hum Pathol; 2021 Oct; 116():39-48. PubMed ID: 34314764
[TBL] [Abstract][Full Text] [Related]
13. Coordinated expression of oestrogen and androgen receptors in HER2-positive breast carcinomas: impact on proliferative activity.
Lin Fde M; Pincerato KM; Bacchi CE; Baracat EC; Carvalho FM
J Clin Pathol; 2012 Jan; 65(1):64-8. PubMed ID: 22039288
[TBL] [Abstract][Full Text] [Related]
14. Overexpression of androgen receptor and forkhead-box A1 protein in apocrine breast carcinoma.
Sasahara M; Matsui A; Ichimura Y; Hirakata Y; Murata Y; Marui E
Anticancer Res; 2014 Mar; 34(3):1261-7. PubMed ID: 24596370
[TBL] [Abstract][Full Text] [Related]
15. Invasive apocrine carcinoma of the breast: clinicopathologic features and comprehensive genomic profiling of 18 pure triple-negative apocrine carcinomas.
Sun X; Zuo K; Yao Q; Zhou S; Shui R; Xu X; Bi R; Yu B; Cheng Y; Tu X; Lu H; Yang W
Mod Pathol; 2020 Dec; 33(12):2473-2482. PubMed ID: 32504034
[TBL] [Abstract][Full Text] [Related]
16. Immunohistochemically defined subtypes and outcome of apocrine breast cancer.
Dellapasqua S; Maisonneuve P; Viale G; Pruneri G; Mazzarol G; Ghisini R; Mazza M; Iorfida M; Rotmensz N; Veronesi P; Luini A; Goldhirsch A; Colleoni M
Clin Breast Cancer; 2013 Apr; 13(2):95-102. PubMed ID: 23245877
[TBL] [Abstract][Full Text] [Related]
17. Androgen receptor expression is a favorable prognostic factor in triple-negative breast cancers.
Zuo T; Wilson P; Cicek AF; Harigopal M
Hum Pathol; 2018 Oct; 80():239-245. PubMed ID: 29902579
[TBL] [Abstract][Full Text] [Related]
18. TRPS1 and GATA3 Expression in Invasive Breast Carcinoma With Apocrine Differentiation.
Wang J; Peng Y; Sun H; Aung PP; Resetkova E; Yam C; Sahin AA; Huo L; Ding Q
Arch Pathol Lab Med; 2024 Feb; 148(2):200-205. PubMed ID: 37074839
[TBL] [Abstract][Full Text] [Related]
19. The Apocrine Profile of Triple-negative Breast Carcinomas in Patients Aged 45 Years or Younger: favorable but rare features.
Masili-Oku SM; Bacchi CE; Fernandes FS; Filassi JR; Baracat EC; Carvalho FM
Rev Bras Ginecol Obstet; 2016 Oct; 38(10):512-517. PubMed ID: 27813039
[No Abstract] [Full Text] [Related]
20. Triple-negative apocrine carcinoma as a rare cause of a breast lump in a Syrian female: a case report and review of the literature.
Ismail S; Kherbek H; Skef J; Zahlouk N; Abdulal R; Alshehabi Z
BMC Womens Health; 2021 Nov; 21(1):396. PubMed ID: 34823507
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
